# Rondecabtagene autoleucel

Source: https://onco.cc/drugs/rondecabtagene-autoleucel/  
OnCo record `rondecabtagene-autoleucel` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rondecabtagene autoleucel is an experimental CAR-T cell therapy from Lyell Immunopharma in phase 3 trials for diffuse large B-cell lymphoma and hodgkin lymphoma, aimed at CD19 and CD20.

## Summary

Rondecabtagene autoleucel (LYL314) is a CAR-T cell therapy developed by Lyell Immunopharma. Its targets are CD19 and CD20 (the sponsor names CD19/CD20). The sponsor states: An autologous, dual-targeting CD19/CD20 CAR T-cell product using an OR-gated CAR construct that fully activates on recognition of either antigen, enriched for CD62L-positive naive/central memory T cells for enhanced proliferation and persistence. ClinicalTrials.gov describes the intervention as: An autologous, dual-targeting CD19/20 CAR T-cell candidate. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07188558 (A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy), in diffuse large B-cell lymphoma and hodgkin lymphoma. The largest, NCT07188558, plans to enrol 400 participants with primary completion expected 2029-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: LYL314
- Modality: CAR-T cell therapy
- Mechanism: An autologous, dual-targeting CD19/CD20 CAR T-cell product using an OR-gated CAR construct that fully activates on recognition of either antigen, enriched for CD62L-positive naive/central memory T cells for enhanced proliferation and persistence.

## Sources

- ClinicalTrials.gov: trials of Rondecabtagene autoleucel: https://clinicaltrials.gov/search?intr=LYL314
- Sponsor pipeline page: http://www.lyell.com/pipeline

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)
- companies: [Lyell Immunopharma](https://onco.cc/companies/lyell-immunopharma/)
- trials: [A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy](https://onco.cc/trials/nct07188558/), [Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma](https://onco.cc/trials/nct05826535/)

---
JSON: https://onco.cc/api/v1/entities/rondecabtagene-autoleucel.json